Basaglar, a Lantus biosimilar, enters the domestic market
Basaglar, a biosimilar product of Lantus(Insulin Glargine), a Sanofi’s basal insulin treatment, will enter the domestic diabetic treatment market.
Lilly Korea, as of the 25th, acquired approval of Basaglar Kwikpen and Cartridge 100IU from the Ministry of Food and Drug Safety.
Basaglar is a biol...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
